The macrophage and its related cholesterol efflux as a HDL function index in atherosclerosis

Area of Science:

• Cardiovascular Science
• Metabolic Disease Research
• Lipid Metabolism

Background:

• Macrophage cholesterol efflux is central to atherosclerosis development and high-density lipoprotein (HDL) function.
• Impaired HDL cholesterol efflux is observed in patients with cardiometabolic diseases, including dyslipidemia, diabetes mellitus, and chronic kidney disease.
• A population-based study shows an inverse relationship between HDL cholesterol efflux capacity and atherosclerotic disease incidence, independent of HDL-cholesterol levels.

Purpose of the Study:

• To review the role of HDL cholesterol efflux in atherosclerosis.
• To evaluate the potential impact of statin treatment on cholesterol efflux.
• To highlight the need for further research into drug effects on cholesterol efflux.

Main Methods:

• Review of recent studies on HDL function and cholesterol efflux.
• Analysis of clinical interventional studies examining statin treatment and cholesterol efflux.
• Synthesis of evidence regarding the association between cholesterol efflux and cardiometabolic diseases.

Main Results:

• Impaired HDL cholesterol efflux is a marker for cardiometabolic diseases and atherosclerosis risk.
• Statin treatment may potentially increase cholesterol efflux, though evidence is limited.
• Current studies on statins lack definitive conclusions due to small sample sizes, varied methodologies, and short follow-up periods.

Conclusions:

• Cholesterol efflux is a promising biomarker for assessing HDL function.
• Further rigorous investigation is required to definitively establish the effect of pharmacological interventions on cholesterol efflux.
• Understanding drug-induced changes in cholesterol efflux may offer new therapeutic strategies for cardiovascular disease prevention.